

The BioAnalytics Group LLC

The BioAnalytics Group Company Overview




The BioAnalytics Group offers services and products that feature the use of biological simulation to help design experiments, analyze data, quantify the effectiveness and toxicity of therapies, and diagnose the presence and mechanisms of disease. Our flagship products include **BioPathwise®** for pathway-centric collaborative research and the newly released **BioPathwise DM** to meet research groups' data management and sharing needs. Licenses for both are available for online purchase at our website, www.bioanalyticsgroup.com.

The BioAnalytics Group LLC offers contract services in the areas of custom assay data analysis, biological modeling, numerical analysis and scientific software development. Our team has 50 years combined experience in modeling, chemical and biological engineering, numerical analysis, algorithm development, data analysis and visualization, and software development for both custom and commercial off-the-shelf applications.


The BioAnalytics Group also provides contract services in every aspect of scientific software development, including analysis, design, development, integration and quality assurance. We craft robust, high-performance software that scientists and engineers trust with their data. We help clients select third-party technology and integrate it with in-house software to provide fast, cost-effective solutions to data analysis and visualization problems. We have extensive experience in finding and fixing defects and performance bottlenecks in large sequential and parallel codes.

Company Overview, Continued



BioPathwise®

Our work with scientists in drug discovery and development led us to create an integrated approach to biological data interpretation—Model Based Assays. **BioPathwise** is our flagship software technology for integrating data, knowledge and powerful analysis tools in a pathway-centric system for research. **BioPathwise** is a key component of our patent-pending approach to assay development—Model-Based Assays™



Common biomarker development challenges

Biomarkers are an increasingly important focus in drug discovery. Assay developers often face some difficult challenges:

- Different assays or assay technologies can give apparently contradictory results.
- Biological variability can result in noisy signals, limiting the throughput of an assay.
- Some activities or concentrations in cells and tissues are expensive, difficult or impossible to measure accurately with current technology.
- Data from screening assays must often be augmented with additional experimental data to identify the mechanisms of action.

We have developed Model-Based Assays to help scientists solve these important problems and to provide additional value from their data.

To contact us:

The BioAnalytics Group LLC
241 Forsgate Drive, Suite 209
Jamesburg, NJ 08831

Phone: 609-632-0091

Email: info@bioanalyticsgroup.com